Articles tagged with Brain Tumors
Researchers at Penn Medicine developed a personalized brain mapping technique using diffusion tensor imaging (DTI) to preserve language, visual, and motor functions during brain tumor surgeries. This technique improved accuracy and extended survival in some cases, with a median survival time of 21.2 months.
Researchers found that blocking substance P binding to its receptor NK1 with the anti-nausea drug Emend halted brain tumor growth and caused cell death in tumor cells. This breakthrough offers new opportunities for studying possible brain tumor treatments.
Johns Hopkins researchers have discovered that mesenchymal stem cells derived from human adipose tissue can seek out and destroy glioblastoma cancer cells in the brain. This innovative approach may provide a new tool for accessing difficult-to-reach areas of the brain where cancer cells proliferate.
Researchers found a high prevalence of low T3 syndrome before and after surgery, associated with unfavorable clinical outcomes and depressive symptoms. Perioperative low T3 syndrome was linked to a five-fold increased risk of poor outcome.
Researchers from Plymouth University have identified the role of Merlin in regulating axon integrity, a key factor in peripheral neuropathy. This discovery could lead to effective drug therapies for patients with neurofibromatosis type 2 (NF2) suffering from peripheral neuropathy.
Researchers identified placental growth factor (PlGF) as crucial for medulloblastoma growth and spread. Blocking this pathway led to regression of all four molecular subtypes in mouse models.
Researchers describe the use of 5-aminolevulinic acid (5-ALA) fluorescence to guide resection of recurrent glioblastoma multiforme, revealing a pathway of tumor spread through brain regions inaccessible to MRI. This technique increases the success of achieving maximum resection.
A new gene, SMARCE1, has been identified as responsible for causing spinal meningioma, an inherited form of tumor. The discovery was made using next-generation sequencing technology and could lead to better testing, treatment, and care for patients.
Researchers discover pairing Avastin with dasatinib can stop lethal spread of aggressive brain cancer glioblastoma multiforme. The combination reduces tumor growth and blocks further spread by inhibiting protein migration.
Researchers developed a diffusion abnormality index (DAI) to measure brain tumor response to radiation therapy. The study showed that changes in DAI can predict post-treatment response with high sensitivity and specificity.
A study published in Neurosurgery found that subcortical damage during awake craniotomy for brain tumor surgery can lead to worsening neurological deficits. The researchers analyzed data from 241 patients and found that 36 developed new neurological abnormalities while the surgeon was operating in the subcortex.
Researchers identified a compound called TIC10 that stimulates the tumor suppression capabilities of TRAIL, inducing cancer cell death in mice. The compound is effective in cancer cell samples and cell lines resistant to conventional therapies, showing promise as a new treatment option for advanced cancer.
A team of researchers at Yale University has identified four new genetic suspects linked to the origins and treatment of meningiomas. The study found that tumors mutated with these genes tend to be located in different areas of the brain, indicating their likelihood of becoming malignant.
Researchers developed a new method to predict individual patient's brain tumor growth, enabling physicians to rapidly identify effective therapies. The approach accounts for tumor features such as shape, density, and growth rate, allowing clinicians to distinguish between patients with different tumor characteristics.
The new book, Navigating Life with a Brain Tumor, offers comprehensive guidance on managing brain tumors, including treatment options, side effects, and coping strategies. Written by neuro-oncologists from Mayo Clinic and Tufts Medical Center, the book aims to empower patients to be active participants in their care.
A research team at Plymouth University has identified a new group of growth factor receptors that signal to brain tumors, which are over-expressed and activated in certain tumors. The study shows that by interfering with the activation, tumor cells can be corrected, paving the way for non-surgical therapies.
A study published in The Lancet found that approximately one of every five individuals with kidney tumors common in patients with tuberous sclerosis complex has had a kidney removed unnecessarily due to misdiagnosis. Everolimus successfully shrinks these tumors, offering an alternative to surgery.
Researchers from Wake Forest Baptist Medical Center found that smaller radiation fields can be safely used to treat glioblastoma patients without compromising treatment efficacy. This study suggests that focusing radiation on smaller areas of the brain may help preserve cognition and reduce symptoms associated with radiation toxicity.
Researchers at Duke Medicine have developed an artificial protein that stimulates the body's natural immune system to fight cancer. In a study published in the Proceedings of the National Academy of Sciences, the therapy was shown to cure brain tumors in six out of eight mice, with no harm to surrounding normal tissue.
Researchers found ID proteins essential for retaining glioma-initiating cells in a specific extracellular niche, maintaining their cancer-promoting properties. The study's results suggest ID proteins as potential therapeutic targets for glioma treatment.
Pitt Cancer Institute researchers have identified over 125 genetic components in a chemotherapy-resistant, brain tumor-derived cell line that could offer new hope for drug treatment to destroy cancer cells. The findings may lead to the development of adjuvant chemotherapy drugs that will improve patient survival rates.
Researchers identified a previously unidentified virus in raccoons that may be contributing to the development of brain tumors. The study found that this virus, dubbed raccoon polyomavirus, is present in all affected animals and may play a role in tumor formation.
Researchers at Barrow Neurological Institute found that a ketogenic diet significantly enhances the anti-tumor effect of radiation, leading to improved survival rates for mice with malignant gliomas. The study suggests that the diet could be used as an adjuvant therapy without FDA approval.
Researchers used PET imaging to evaluate tumor grade and cellular proliferation in patients with gliomas. The study found that F-18-FLT PET provided a more comprehensive view of tumor grade and correlated with overall survival, making it a valuable tool for guiding treatment.
A new study found a four-fold increase in breast cancer incidence among women with neurofibromatosis-1, prompting recommendations for earlier screening. The researchers suggest annual manual breast exams and mammograms beginning at age 40 for this high-risk population.
Researchers found that natural killer cells in patients quickly eliminate anticancer viruses used to treat brain tumors, reducing their effectiveness. Blocking these immune cells may help improve treatment outcomes for glioblastoma patients.
Pituitary centers of excellence could provide optimal clinical management for patients with pituitary tumors, highlighting the importance of multidisciplinary collaborative environments. The proposal suggests three key missions: comprehensive patient care, residency training, and research contributions.
A new Johns Hopkins research suggests that uninsured brain cancer patients are twice as likely to die in the hospital after undergoing surgery to remove a tumor. Despite this, patients with government-subsidized insurance through Medicaid had survival rates closer to those with private insurance.
A study published in Archives of Surgery found that uninsured patients with brain tumors had higher in-hospital mortality rates than privately insured patients. The disparity was pronounced in teaching hospitals, highlighting the need for further research into insurance-related disparities in medical outcomes.
Sanford-Burnham researchers found that different brain tumor cell types respond to distinct treatments due to varying growth factor regulation. This discovery offers potential for more effective and less harmful treatments tailored to individual tumors.
A recent Johns Hopkins study found that repeated surgeries to remove glioblastomas, the most aggressive brain tumors, can increase median survival time from 14 months to 26.6 months. This may be due to increased efficacy of radiation and chemotherapy with each successive surgery.
A phase 2 study reports that the combination of lapatinib and capecitabine reduces brain tumour size by at least 50% in two-thirds of women with advanced HER2-positive breast cancer. This treatment delays radiotherapy, which can impair cognitive function, offering a potential advance for patients.
Researchers at the Salk Institute have discovered that glioblastoma multiforme (GBM) can originate from cortical neurons, challenging previous assumptions about its origins. This finding suggests potential new targets to treat these deadly brain tumors and may help slow progression and recurrence.
A joint UMCP and UMB research project has been awarded a new $2 million grant to continue developing a small robot that could aid neurosurgeons in removing difficult-to-reach brain tumors. The robot, called MINIR-II, is fully MRI-compatible and will be controlled by the physician, with targeting information obtained from real-time MRI.
Researchers at Barrow Neurological Institute and Arizona State University have made a breakthrough in understanding why brain tumors are difficult to treat. The study reveals that the immune system behaves differently in different regions of the brain, including tumors, leading to potential limitations in effective treatment.
Scientists have developed a new video protocol to isolate brain tumor initiating stem cells from primary brain tumors, allowing for quick and efficient analysis of target cells. This approach has been effectively used to identify similar stem cells in leukemia patients.
Recent research in epigenetics has identified two key tests that can predict brain tumor sensitivity to temozolomide and distinguish prostate cancer from benign growth. New epigenetic biomarkers are being rapidly developed to predict treatment performance and weaknesses of tumors.
A specific genetic variation found in people who carry a 'G' instead of an 'A' at a particular spot in their genetic code is associated with a six-fold higher risk of developing certain types of brain tumors. Researchers hope this discovery will lead to better surveillance and diagnosis.
A genetic variant associated with a six-fold higher risk of developing certain brain tumors has been identified by researchers at UCSF and Mayo Clinic. The study found that individuals carrying the 'G' version of the variant have slower-growing gliomas, which could lead to better surveillance, diagnosis, and treatment.
Researchers at Cedars-Sinai Medical Center found that multifocal glioblastoma patients have significantly shorter overall survival compared to those with single tumors, even when treated with the same therapies. Median overall survival for multifocal patients was six months, while single-tumor patients survived 11 months.
Researchers at UT MD Anderson Cancer Center show how PKM2 contributes to brain tumor formation and growth by influencing histone proteins. Higher levels of PKM2 expression and H3 phosphorylation are correlated with shorter survival and higher grade tumors.
A new experimental immune-based therapy has more than doubled median survival of patients diagnosed with the most aggressive malignant brain tumor. The vaccine targets six antigens involved in glioblastoma cell development and shows promise in attacking cancer stem cells.
Genomic deletions in cancer cells eliminate tumor-suppressor genes, but also expose vulnerabilities to other essential genes. Researchers found that targeting the redundant function of these genes can kill malignant cells. The study identified ENO1 and ENO2 as key targets for therapy.
A new method allows for personalized clinical trial predictions by analyzing cell behavior, offering ways to improve cancer treatment outcomes and predict tumor response. The approach may enable oncologists to test combinations of targeted therapies in individual patient tumors.
A new study found that individuals with allergies had a significantly lower risk of developing glioma, a type of brain tumor. Women were more likely to benefit from this reduced risk, with those testing positive for elevated allergen-specific IgE experiencing a 54% decrease in glioblastoma risk.
A UT Southwestern Medical Center study reveals that glioblastoma multiforme (GBM) recurs due to slower-growing 'cancer stem-like' cells. Researchers identified these cells as a potential target for future therapies, offering new hope for treatment.
Researchers at Stanford University School of Medicine have identified several gene mutations responsible for the most common childhood brain tumor, medulloblastoma. The study suggests that these tumors can be categorized into genetically distinct groups with different prognoses and resistance to standard treatments.
Scientists at Washington University School of Medicine found that stem cells from a specific part of the developing brain contribute to brain tumors caused by neurofibromatosis type 1. The study suggests that understanding the unique characteristics of these stem cells may lead to more effective treatments for pediatric brain tumors.
Researchers discovered that bevacizumab can lead to invasive tumors in brain cancer patients, but found a new treatment strategy by targeting both VEGF and MET. This approach may improve survival rates for drug-resistant patients, offering hope for a more effective treatment.
Researchers have discovered genes that cooperate in tumor development and identified potential new drug targets for the most aggressive subtype of medulloblastoma. The study found alterations linked to subtypes with the best and worst prognosis, offering new direction for understanding what drives these tumors.
Researchers at the University of Nottingham have discovered three sets of genetic markers that could improve diagnosis and treatment outcomes for children with a rare type of brain tumor. The study found distinct genetic signatures for each sub-type of tumor, which may lead to more effective tools for predicting patient outcomes.
Johns Hopkins researchers discovered a cellular mechanism driving meningioma growth and progression. The study identified the activation of YAP1 protein in nuclei as a crucial step in tumorigenesis, suggesting new treatment targets.
A recent study published in Nature Genetics provides evidence that genetic variations in the embryo may predispose individuals to cancer later in life. The study found that mutations in key genes were present in cells of patients with congenital skin lesions, suggesting an early origin for some tumors.
A theoretical model simulates brain tumor cell evolution under treatment, revealing that peripheral cells need to be targeted. The model suggests enhancing TTF treatment by applying specific frequencies, leading to increased plasma membrane permeability and cancer cell demise.
A new study found that folic acid fortification of foods may lower the incidence of certain types of childhood cancer in the US. Incidence reductions were found for Wilms' tumor and primitive neuroectodermal tumors, two types of cancer previously associated with neural tube defects.
Researchers have revised the glioblastoma classification system to accommodate treatment advances and molecular markers, aiming to better identify patients requiring aggressive therapy. The new system incorporates clinical variables, molecular biomarkers, and tumor characteristics to provide a more relevant prognosis.
Researchers developed a genetic test to predict ocular melanoma tumor spread, classifying tumors with over 97% accuracy. The test identified two classes of tumors: those unlikely to spread (class 1) and those more likely to develop metastatic cancer (class 2).
Researchers have discovered that children's brain tumors preserve characteristics of the normal cells from which they originate, offering new hope for effective treatments. The study found that tumour malignancy is linked to cellular origin and time of tumour development, improving prospects for targeted therapies.
Researchers build 'spaghetti models' of cancer progression using mathematical models, predicting tumor growth, response to treatments, and risk of recurrence. This approach combines clinical imaging with biological experiments and mathematical modeling to develop patient-specific medicine.
Researchers have discovered that the NKCC1 protein may hold key to understanding how glioblastoma, the deadliest type of brain cancer, moves and invades healthy brain tissue. Blocking NKCC1 with a cheap FDA-approved drug slows movement of glioblastoma cells, suggesting a potential new approach to treat this aggressive cancer.